COMBINED INTRAOPERATIVE RADIATION AND PERIOPERATIVE CHEMOTHERAPY FOR UNRESECTABLE CANCERS OF THE PANCREAS

Citation
M. Mohiuddin et al., COMBINED INTRAOPERATIVE RADIATION AND PERIOPERATIVE CHEMOTHERAPY FOR UNRESECTABLE CANCERS OF THE PANCREAS, Journal of clinical oncology, 13(11), 1995, pp. 2764-2768
Citations number
32
Categorie Soggetti
Oncology
ISSN journal
0732183X
Volume
13
Issue
11
Year of publication
1995
Pages
2764 - 2768
Database
ISI
SICI code
0732-183X(1995)13:11<2764:CIRAPC>2.0.ZU;2-W
Abstract
Purpose: To evaluate the effectiveness of combined intraoperative radi ation therapy (IORT) and perioperative chemotherapy in the management of unresectable pancreatic cancer. Materials and Methods: Forty-nine p atients with localized unresectable adenocarcinoma of the pancreas wer e treated in a multimodality program of initial IORT and perioperative chemotherapy (fluorouracil [5-FU]/leucovorin) followed by combined ex ternal-beam radiation (40 to 55 Gy) and continued chemotherapy. Patien ts were evaluated for toxicity, pattern of failure, and survival, The follow-up times of these patients range from a minimum of 12 months to a maximum of 62 months, with a median of 28 months. Results: The inci dence of perioperative mortality was 0%. Early postsurgical morbidity (grade 3/4) was observed in seven of 49 patients (14%) and late treatm ent-related morbidity (grade 3/4) in eight of 43 patients (19%) alive beyond 6 months, Morbidity was primarily gastrointestinal (GI), with n o hematologic toxicities observed, The median survival time in the tot al group of patients is 16 months, with a 2-year survival rate of 22% and a 4-year survival rate of 7%, Freedom from local progression of di sease was achieved in 71% of patients. Conclusion: The patients who un dergo IORT with electrons and treated with perioperative chemotherapy (5-FU leucovorin) followed by additional external-beam radiation and c hemotherapy appear to have improved survival, with few early or lore c omplications, Dose escalation of external-beam radiation and chemother apy may further improve local control of disease and survival of patie nts. (C) 1995 by American Society of Clinical Oncology.